PressSeptember 30, 2022 PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022
PressSeptember 29, 2022 Nova Mentis Psilocybin Microdose Capsule Formulation to be Submitted in Health Canada Phase 2A Clinical Trial Application
PressSeptember 29, 2022 Biomind and Queen’s University of Belfast Receive Controlled Substances License to Commence the Production of a Novel Transdermal Drug Delivery System
PressSeptember 29, 2022 Reunion Neuroscience Inc. Appoints Greg Mayes as President and Chief Executive Officer
PressSeptember 28, 2022 Silo Pharma Announces Uplisting to Nasdaq Capital Market and Pricing of $5 Million Public Offering of Common Stock
PressSeptember 28, 2022 atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01
PressSeptember 28, 2022 Silo Wellness Executes Definitive Agreement to Acquire Dyscovry Science and Its Psilocybin Pharmaceutical Biosynthesis and Research Portfolio
PressSeptember 28, 2022 Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds
PressSeptember 27, 2022 Tryp Therapeutics Strengthens Intellectual Property Portfolio with Provisional Patent Applications for Fibromyalgia Treatment and for Crystalline Forms of TRP-8803
PressSeptember 26, 2022 Wellbeing Subsidiary KGK Science Opens New Clinical Research Center to Reimagine a Healthier Future
PressSeptember 24, 2022 Irwin Naturals Inc Announces Normal Course Issuer Bid for Subordinate Voting Shares of the Corporation
PressSeptember 24, 2022 Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada
PressSeptember 24, 2022 Core One Labs Signs Letter of Intent with GMP Manufacturing Partner for Production of Proprietary Psychedelic Compounds
PressSeptember 24, 2022 Mydecine Innovations Group Announces Closing Under Share Subscription Agreement and Welcomes New CFO
PressSeptember 22, 2022 Origin Therapeutics’ Portfolio Company, Xpira Pharmaceuticals, Receives FDA Approval For Psilocybin Trial IND Application
